🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

3rd doses versus booster has caused much confusion. This is why immunosuppressed people needed a 3rd (catch up) dose urgently 👇 (with a mRNA vaccine). Only 55% of tx patients had detectable Abs 1/2 Prof Liz B 🇬🇧🇮🇱🇺🇦🇵🇸 Maria Tina Thomson Candice Clarke thelancet.com/journals/lance…

Booster doses for these people is planned 6mths after catch up dose NHSE have told GPs/Trusts to contact/arrange 3rd doses for their eligible patients by 11th Oct x.com/KatharineDC/st… Stephen McAdoo @sarah_gleeson_ @PJPMartin Helena Edwards

Immunosuppressed patients are less protected than the rest of the vaccinated population, and further action will be needed if not resolved after the deadline next week. The UK Kidney Association Kidney Care UK @kidneycareuk.bsky.social Fiona Loud 💙 Frank Dor BTS Kidney Research UK BBC Health News

Impt data from Imperial NHS 💙 Imperial Medicine -only 55% #immunosuppressed #patients had detectable antibodies after 2 doses #Covidvaccine. Led by Michelle Willicombe Maria. Urgent need for clarity: All immunosuppressed: 3rd primary dose now (8wks after 2nd) THEN booster 6mths later

📕 New in The Lancet: Our researchers outline why a third mRNA COVID #vaccine dose is urgently needed for #immunosuppressed people. Read the paper from Michelle Willicombe, Maria Prendecki, Tina Thomson, Candice Clarke, Prof Liz B 🇬🇧🇮🇱🇺🇦🇵🇸 et al👇 thelancet.com/journals/lance…

New Comment online! Maria Prendecki, Michelle Willicombe and Stephen McAdoo discuss COVID-19 vaccination in patients with immunity-mediated kidney disease. go.nature.com/3b1g92Z

Beautiful work presented by Maria on role of #SyK in #AAV - tissue & multiple cell type analysis. #Sykinhibition in #patients next? #RSMNephrology Stephen McAdoo Kavita Gulati Kidney Research UK

Delighted to be part of #MELODY study - funded by Kidney Research UK Medical Research Council Vasculitis - In memory of John Mills MBE 💙💚 Cystic Fibrosis Trust Blood Cancer UK; sponsored by Imperial College London and led by the indefatigable Michelle Willicombe along with Stephen McAdoo DrFiona_Pearce Peter Lanyon Clinical Trials Unit NHS Blood+Transplant Sean Hua Lim & more 1/

The #MELODY Study is now live for transplant recipients! Register here with your NHS number: melodystudy.org BTS NHS Blood+Transplant Invites to patients with blood cancer and autoimmune diseases - including vasculitis - are coming soon… Vasculitis - In memory of John Mills MBE 💙💚 BSR

Comparative immunogenicity of heterologous versus homologous 3rd SARS-CoV-2 vaccine doses in kidney transplant recipients medrxiv.org/content/10.110… 700 patients studied (AZ/AZ/Pfizer or Pfizer x3) 24% of infection naive patients had no detectable Ab post 3rd dose

We are recruiting! jobs.imperial.nhs.uk/job/v3879366 Imperial NHS 💙 College Renal and Transplant Centre. Trust Fellowship : 75% clinical time,covering all aspects of renal and transplant medicine and 25% research time Prof Liz B 🇬🇧🇮🇱🇺🇦🇵🇸 Stephen McAdoo Michelle Willicombe Edwina Brown

Immune responses following 3rd and 4th doses of heterologous and homologous COVID-19 vaccines in kidney transplant recipients medrxiv.org/content/10.110… Our (UK) data 1. 19% of transplant patients have no Ab responses post 4 💉 2. Only 20% have detectable T-cell responses 1/3

3. Ab levels post-V4 weaker if seroconverted after V4<V3<V2 4. Vaccine combination less important 5. Immunosuppression burden still matters 2/3

Large spectrum of responses, especially when include those who have been exposed to infection. 3/3 So priority for protection remains the non-responders. More data to come later this week. MELODY Study Imperial Transplant Group Vicky Foxcroft 💙 Wes Streeting Andrew Gwynne MP Miranda Scanlon

Really pleased to be able to offer this pilot programme to wait list and transplant patients (where blood transfusion is unavoidable). Any modifiable measures to prevent/avoid HLA antibody development should be taken in tx patients. NHS Blood+Transplant Michelle Willicombe Imperial Department of Immunology & Inflammation

🚨 Visual Abstract Alert! ORIGIN Trial: Atacicept for treatment of IgA Nephropathy ✅✨ #GlomConHawaii GlomCon

Calling all talented students 📣 Intetested in Immunology? Come join our friendly group for your PhD! 10 more days to apply 👇#PhD #immunology #allergy

It took a while...but the main output from the MELODY Study is finally out in The Lancet So much to be learnt from >28k recruits, to be applied now and for future protection of immunocompromised individuals (who do not all have the same risk!) 1/3 thelancet.com/journals/lance…

Wonderful talk by Candice Roufosse presenting Transplant Renal Pathology Updates from the Banff 2024 meeting #ERA2025